Episode Overview

The latest episode of WTF with Nikhil Kamath brings together two of India’s most influential pharmaceutical leaders – Rajeev Juneja, Co‑Founder and Managing Director of Mankind Pharma, and GV Prasad, Co‑Chairman and CEO of Dr. Reddy's Laboratories – for an unscripted conversation on the evolution of India’s healthcare and pharmaceutical landscape.

Mankind Pharma Growth

Juneja explains that Mankind Pharma was founded in 1995 with an initial capital of Rs 69,000. The company deliberately targeted smaller markets in Western Uttar Pradesh, Haryana and Punjab, focusing on depth of distribution rather than breadth. By pricing its products 40 to 60 percent below competitors, Mankind made medicines more affordable and built a strong presence in underserved regions. Today, Mankind Pharma ranks as India’s fourth‑largest pharmaceutical company, with revenues exceeding Rs 40,000 crore.

Dr. Reddy's Evolution

Prasad recounts joining Dr. Reddy's in 1990 when the group’s total revenue was less than Rs 100 crore. Over three decades, he helped transform the firm into a nearly USD 3 billion global business that now operates across generics, biosimilars and proprietary drug discovery platforms. He differentiates between generics, biologics and innovative medicines, highlighting the company’s expanding portfolio.

Industry Insights and Innovation Frontier

Both leaders agree that while India dominates the generic medicines segment, the next growth frontier lies in innovation‑driven drug discovery. They discuss emerging therapeutic areas such as GLP‑1 drugs, the economics of drug development, and the capital, talent and research infrastructure required to build a globally competitive innovation ecosystem.

Competitive Landscape with China

Juneja and Prasad compare India’s position to China’s rapid ascent. They note that 29 percent of all new cancer drugs now originate from Chinese companies, reflecting China’s shift from low‑cost manufacturing to a focus on pharmaceutical innovation.

API Manufacturing Perspective

Addressing the ongoing debate around Active Pharmaceutical Ingredients (APIs), Prasad argues that India has not lost its manufacturing capability but faced economic challenges that temporarily shifted production abroad. Juneja adds that Indian firms are increasingly partnering with and licensing molecules from global innovators to accelerate the delivery of advanced therapies to patients.

Career Guidance for Young Professionals

The conversation also offers advice for aspiring pharma professionals. Juneja shares his early experience as a medical representative, while Prasad reflects on his journey from a junior role to leading a global enterprise. Both emphasize opportunities across science, research, manufacturing, sales, entrepreneurship and healthcare innovation.

Host Commentary

Nikhil Kamath observes that “by volume, India is the pharmacy of the world, but by revenue, we’re barely a rounding error,” and underscores the strategic question of how the country can shift from volume‑driven generic leadership to high‑value innovative drug development.

The full episode is available on YouTube.